GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study

The combination of GFH018 and toripalimab showed a manageable toxicity profile and durable antitumor activity in patients with R/M NPC, especially those without prior ICI exposure.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-06-13
DOI
https://doi.org/10.1158/1078-0432.ccr-25-0085
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study

Sai-Lan Liu, Muh‐Hwa Yang, Hai‐Qiang Mai, Xiaozhong Chen et al.
1 citations
Clinical Cancer Research
Lung Cancer Treatments and Mutations
1.52
article

GFH018 and Toripalimab Combination Therapy for Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: Results from a Phase Ib/II Study

Sai-Lan Liu, Muh‐Hwa Yang, Hai‐Qiang Mai, Xiaozhong Chen, Mun N. Hui, Ye Guo, Yujuan Zhou, Lin‐Quan Tang, Hua-Qiang Zhu, Hanjie Shen, Hui‐Ching Wang, Qun Li, Shan-Shan Guo, Li-Ting Liu, Li‐Tzong Chen, Kunyu Yang, Shuang Wang, Yi-Shing Leu, Yu Wang, Qiu-Yan Chen
article en
1 citations

Abstract

The combination of GFH018 and toripalimab showed a manageable toxicity profile and durable antitumor activity in patients with R/M NPC, especially those without prior ICI exposure.

Clinical Cancer ResearchVol. 31(16)
Central South University (CN), National Yang Ming Chiao Tung University (TW), Kaohsiung Medical University (TW), Sun Yat-sen University (CN), National Health Research Institutes (TW), Mackay Memorial Hospital (TW), Taipei Veterans General Hospital (TW), Fudan University Shanghai Cancer Center (CN), Chris O’Brien Lifehouse (AU), Zhejiang Cancer Hospital (CN), Hunan Cancer Hospital (CN), Shanghai East Hospital (CN), Sun Yat-sen University Cancer Center (CN), Io Therapeutics (United States) (US), Regend Therapeutics (China) (CN), Hangzhou Cancer Hospital (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Openalex Percentile: Top 17%
Lung Cancer Treatments and Mutations
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.